Albright Charles 4
4 · Editas Medicine, Inc. · Filed Dec 8, 2020
Insider Transaction Report
Form 4
Albright Charles
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
2020-12-07$16.51/sh+20,000$330,200→ 44,907 total - Sale
Common Stock
2020-12-07$40.02/sh−20,000$800,400→ 24,907 total - Exercise/Conversion
Stock Option (right to buy)
2020-12-07−20,000→ 165,000 totalExercise: $16.51Exp: 2026-09-08→ Common Stock (20,000 underlying)
Footnotes (3)
- [F1]The exercise and sale reported in this Form 4 was effected pursuant to a 10b5-1 plan adopted by the Reporting Person on May 15, 2020.
- [F2]This transaction was executed in multiple trades at prices ranging from $40.00 to $40.06. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F3]This option was granted on September 9, 2016 and vested over four years with 25% of the shares having vested on August 22, 2017, and the remaining 75% of the shares having vested in equal monthly installments thereafter through August 22, 2020.